PI 3-Kinase Signaling Pathways in Disease Organizer(s): Peter M. Finan and Lewis C. Cantley Date: February 15 - 20, 2007
Location: Hilton Santa Fe Historic Plaza Hotel, Santa Fe, NM, USAThe PI 3-kinase signaling pathway is emerging as a promising therapeutic target in a number of human diseases including cancer, inflammation and heart disease. Mutations in the PIK3CA gene and the deletion of lipid phosphatase, PTEN, are widespread in many tumors. Mouse models which target individual PI 3-kinase isoforms have shed light on the roles of these enzymes in immune cell function, mast cell degranulation and leukocyte migration. One of the most exciting developments in this field is the discovery of new PI 3-kinase inhibitors. However, identifying the indications that will provide the best opportunity to develop these inhibitors is the subject of intense debate. This meeting aims to bring together scientists and clinicians from academia and industry to discuss the opportunities and liabilities of targeting the PI 3-kinase pathway in disease, drawing on human pathophysiology and genetics, mouse models and preclinical data with new PI 3-kinase inhibitors. Scholarship Deadline: October 16 2006 Discounted Abstract Deadline: October 16 2006 Abstract Deadline: November 15 2006 Discounted Registration Deadline: December 15 2006 We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Abbott Laboratories
Novartis Pharma AG
TargeGen, Inc.
|